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Abstract 
The interferon regulatory factor 5 (IRF5) gene encodes a transcription factor that plays an 
important role in the innate as well as in the cell-mediated immune responses. The IRF5 
gene has been shown to be associated with systemic lupus erythematosus and rheumatoid 
arthritis. We studied whether the IRF5 gene is also associated with inflammatory bowel 
diseases (IBD), Crohn disease (CD) and ulcerative colitis (UC). Twelve polymorphisms 
in the IRF5 gene were genotyped in a cohort of 1007 IBD patients (748 CD and 241 UC) 
and 241 controls from Wallonia, Belgium.  The same polymorphisms were genotyped in 
a confirmatory cohort of 311 controls and 687 IBD patients (488 CD and 192 UC) from 
Leuven, Belgium. A strong signal of association (p = 1.9 x 10-5, OR: 1.81 (1.37-2.39)) 
with IBD was observed for a 5bp indel (CGGGG) polymorphism in the promoter region 
of the IRF5 gene. The association was detectable (p = 6.8 x 10-4) also in CD patients, and 
was particularly strong among the UC patients (p = 5.3 x 10-8, OR 2.42 (1.76 -3.34)). The 
association of the CGGGG indel was confirmed in the second cohort (p = 3.2 x 10-5, OR 
1.59 (1.28 – 1.98)). The insertion of one CGGGG unit is predicted to create an additional 
binding site for the transcription factor SP1. Using an electrophoretic mobility shift assay 
we show allele-specific differences in protein binding to this repetitive DNA-stretch, 
which suggest a potential function role for the CGGGG indel.  
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Introduction 
The chronic inflammatory bowel diseases (IBD), Crohn disease (CD) and ulcerative 
colitis (UC), are common causes of gastrointestinal morbidity in Western countries. 
These diseases are caused by the interaction of genetic, immunologic and environmental 
factors (1). The role of genetic factors in IBD is supported by a strong familial clustering 
of the disease and by the significantly higher disease concordance between MZ twins 
than between DZ twins (2-6).  A genetic predisposition to CD has been demonstrated and 
validated for few genes (CARD15, DLG5, IL23R, ATG16L1), and several genomic 
regions were high lighted by recent genome-wide association (GWA) scans with SNP 
markers (7-9).  The associations of the CARD15 and the IL23R genes with CD were 
recently confirmed by a GWA study performed on a large case-control population by the 
Welcome Trust Case Control Consortium (WTCCC) (10). Moreover, this study identified 
four new strong association signals at the chromosomal locations 3p21, 5q33, 10q24 and 
18p11, which were subsequently replicated in an independent cohort of CD patients (11). 
In addition to being shared within the two IBD disease groups, CD and UC, some genes 
could also be involved in the pathogenesis of other autoimmune diseases. Autoimmune 
diseases affect up to 5% of the Western population, and they are characterized by a loss 
of self-tolerance leading to immune-mediated tissue destruction. Autoimmune diseases 
are multifactorial diseases that may have a shared genetic background, as supported by a 
higher frequency of immune–mediated disorders in families with immune diseases than 
in the general population and by the higher rate of co-occurrence of immune diseases in 
patients affected by immune disorders (12, 13). Some loci or genes are known to be 
shared between auto-immune diseases: the HLA region, the cytotoxic T-lymphocyte 
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antigen-4 (CTLA-4) gene in Graves' disease (GD), Hashimoto thyroiditis and type 1 
diabetes (T1D) or the PTPN22 gene in rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), GD and T1D (14-16).The recent WTCCC GWA study reported 
several loci implicated in more than one disease. By grouping three auto-immune 
diseases (RA, CD and T1D), four regions on chromosomes 4, 10, 12 and 18 showed high 
association signals (10).Although the pathogenesis of IBD is uncertain, IBD can be 
considered as autoimmune diseases, or maybe more appropriately as “immune 
dysregulation diseases”(17). Mutations in genes implicated in the immune regulation and 
response could lead to an immune dysregulation that predisposes to immune diseases.  
 
The interferon (IFN) regulatory factor (IRF) family comprises nine transcription factors 
involved in the defense against microbes, in cellular survival and hematopoietic 
development. Some members of the IRF family are activated in response to infections 
and are consequently involved in innate immunity (18-20). IRF3 and IRF7 are direct 
transducers of virus-mediated signaling, whereas IRF5 has a role in the response to 
kinases involved in viral infections or in Toll-like-receptor (TLR) signaling (21, 22). 
IRF5 acts as repressor or activator of type I interferon genes, but also as inducer of pro-
inflammatory cytokines, such as interleukin-6 (IL-6), IL-12 and tumor-necrosis factor-
alpha. IRF5 is crucial for the induction of these proinflammatory cytokines by the TLR –
MYD88 pathway and plays a central role in the recently described synergism between the 
TLRs (18, 23-26). The implication of these cytokines in IBD is well documented, and has 
led to the development of specific therapeutic agents against these cytokines or their 
receptors (27).  
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 The IRF5 gene, located on 7q32, displays a strong association with SLE (28). This 
association is well established and has been replicated in several independent patient 
cohorts (29). Moreover the IRF5 gene has recently been shown to be associated with 
rheumatoid arthritis (30). Given the role of IRF5 in innate and cell-mediated immunity 
and the described association with two important autoimmune diseases, SLE and RA, we 
postulated that the IRF5 gene could be part of the genetic background that leads to the 
development of multiple immune diseases, including IBD. To test this hypothesis, twelve 
polymorphisms in the IRF5 gene were genotyped in IBD patients from Belgium. Six of 
the polymorphisms displayed an association with IBD, with an exceptionally strong 
association signal for a 5 bp insertion-deletion polymorphism (CGGGG indel) in the 
promoter region of the gene. This association was observed with both CD and UC, and 
we were able to confirm these results in an independent cohort of IBD patients. We also 
demonstrated differential protein binding to the two alleles of the CGGGG indel using an 
electrophoretic mobility shift assay.  
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Results 
Twelve polymorphisms in the IRF5 gene were tested for their association with IBD, CD 
or UC, in a cohort of Caucasian patients and controls from Wallonia in Belgium. These 
polymorphisms were selected for our study based on their previously described 
association with SLE or RA (28-30), or their potential functional roles (Table 1). The 
polymorphisms analyzed were 10 single nucleotide polymorphisms (SNPs) and two 
insertion/deletion polymorphisms (indels). Five SNPs (rs729302, rs4728142, rs3757385, 
rs2004640, rs3807306) and a 5 bp indel (CGGGG) are located in the promoter or first 
intron of the IRF5 gene. The CGGGG indel was included as a potentially functional 
variant because it is predicted to alter a binding site for the transcription factor SP1 
("TFSEARCH: Searching Transcription Factor Binding Sites", 
http://www.cbrc.jp/research/db/TFSEARCH.html/) (31). The other indel is a deletion of 
30 bp in exon 6 that removes ten amino acids from the IRF5 protein (32). Figure 1 shows 
the location of the SNPs and indels in the IRF5 gene. 
 
We found that six of the polymorphisms, including SNPs rs4728142, rs3807306, 
rs10954213, rs11770589 and both indels appear to be associated with IBD (p < 0.05), 
with the strongest association signal for the CGGGG indel (p = 1.9 x 10-5). The 
association analysis for each polymorphisms reveals strong association signals for the 
CGGGG indel in the UC subgroup (p = 5.3 x 10-8, OR 2.43 (1.76-3.34)). Association 
signals were also observed in the CD patients, particularly for the CGGGG indel (p = 6.8 
x 10-4, OR 1.64 (1.23-2.17)) (Table 2). To confirm the association between the IRF5 
polymorphisms and IBD, they were genotyped in an independent cohort of IBD patients 
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from Leuven, Belgium, and tested for their association with IBD, CD and UC (Table 3). 
The CGGGG indel that was the most strongly associated polymorphism in the cohort 
from Wallonia was also associated in the Leuven cohort (p = 3.2 x 10-5, OR 1,59 (1.28 -
1.98)), while no association signal was observed for the other polymorphisms. In the 
combined analysis of both cohorts (1661 IBD patients), the association signals from the 
CGGGG indel and the SNP rs4728142 are maintained, with a strong signal for the 
CGGGG indel (p= 1.4 x 10-8 OR 1.62 (1.37-1.92)). Both patient subgroups (CD and UC) 
were also considered in the combined analysis, with strong association signals for the 
CGGGG indel in both subgroups (p = 3.3 x 10-6 in CD and p = 7.9 x 10-10 in UC), and 
also a strong signal in UC for the SNP rs4728142 (p = 4.2 x 10-5). Table 4 shows the p-
values and odds ratio (OR) for all the analyzed polymorphisms when the data from both 
cohorts are combined.  
It is notable that two of the SNPs, rs2070197 located in the 3’UTR and rs12539741 
located 5 kb downstream of the IRF5 gene do not show any signals for association with 
IBD in our cohorts, although these two SNPs which are in perfect LD with each other 
have been found to be strongly associated with SLE (see Table 1 and references therein). 
These two SNPs are in perfect LD with the HapMap SNP rs10488631 (32), which is in 
perfect LD with several additional HapMap SNPs distributed over a 100 kb region 
located in 3’ of the IRF5 gene which contains the transportin 3 (TNPO3) gene.  The pair-
wise LD between these SNPs and the polymorphism that was most strongly associated 
with IBD, the CGGGG indel, is low with an r2-value of 0.10 in our control groups from 
both cohorts (Figure 2). Figure 2 also shows that this CGGGG indel is correlated to the 
SNPs rs4728142 (r2 = 0.77) and rs3807306 (r2 = 0.65), that showed association signals 
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with IBD, and that the pairwise LD-values between these SNPs and the SNPs rs2070197 
and rs12539741 is low (mean r2 = 0.10, maximum 0.11). 
 
We performed haplotype analysis of the six IRF5 polymorphisms located in the promoter 
and first intron of the IRF5 gene. Four major haplotypes (frequency > 10%) were 
identified. The haplotype analysis did not reveal any association signals that were 
stronger than the signal from the 5 bp CGGGG indel alone (data not shown). The 
frequency of the minor allele, corresponding to the insertion of CGGGG (the 4 x 
CGGGG allele) in the promoter region of the IRF5 gene, is higher in IBD patient than in 
the controls. A single copy of the minor (risk) allele was associated with IBD with an OR 
of 1.62 (1.37-1.91), while two copies of the risk allele were associated with an OR of 
3.03 (2.04-4.49). Thus the CGGGG insertion confers a very strong risk for IBD, CD or 
UC in the Belgian population.  
 
Given the in silico prediction that the insertion of CGGGG alters a binding site for the 
transcription factor SP1, we used EMSA to test for differential protein binding to the two 
alleles of the CGGGG indel using probes specific for 4 and 3 CGGGG repeat units. The 
EMSA revealed a clearly higher level of protein binding to the 4 x CGGGG probe than to 
the 3 x CGGGG probe (Figure 3)  
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Discussion 
A genetic etiology in IBD is well established, but the complete set of the underlying 
genetic variants and their epistasis remain to be elucidated. For about 30 years, genetic 
factors predisposing to IBD have been searched for, beginning with the implication of 
different HLA phenotypes in the predisposition to CD (33). Recent GWA studies have 
identified several loci and genes that are putatively associated with CD (7-9, 34). Genome 
wide linkage studies and association studies of “CD susceptibility genes” on UC cohorts 
have demonstrated that CD and UC share some, but not all disease-predisposing genes 
(35, 36). For example, associations of the CARD15 and ATG16L genes have been 
reported only with CD, while an association signal for IL23R gene validated in CD 
appears also, although weaker, in UC (6, 37, 38).  Here we report an association of 
polymorphisms in the IRF5 gene with both CD and UC. IRF5 is the first gene associated 
with UC to be validated in a confirmatory cohort, where a stronger association signal is 
observed in UC (OR = 1.93 (1.56 – 2.38)) than in CD (1.51 (1.27 – 1.80)). Several loci 
predisposing to IBD have already been explored in SLE, such as the IBD5 locus, the 
CARD15 gene and the discs large homolog 5 gene (DLG5), but no associations with SLE 
have been confirmed for these genes (39-41). Hence, our study provides the first 
confirmed evidence of a shared gene between SLE and IBD. Our findings of association 
with IBD diverge from those in SLE, where one group of SNPs in the promoter and first 
intron of the IRF5 gene and another group of SNPs tagged by the SNP rs2070197 or its 
proxies in the 3’-region downstream of the IRF5 gene, which contains the TNPO3 gene, 
seem to be independently associated with the disease (42). In our study we observe 
association signals with IBD from SNPs that belong to the first group of SNPs only, 
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while we do not observe any association between IBD and the latter group of SNPs. Thus 
our data indicate clearly the IRF5 gene as susceptibility factor for IBD, and reveal an 
unlikely role in IBD for SNPs located 3’ of IRF5 and in the TNPO3 gene. A haplotype 
formed by four linked SNPs that belong to the first group of SNPs in the promoter region 
of IRF5 is associated with RA (30), but none of the SNPs located in the 3’-region of the 
IRF5 gene that are tagged by the SNP rs2070197 has to our knowledge been tested for 
their association with RA. 
We observed the strongest signal of association with IBD for a 5bp CGGGG indel in the 
promoter region of IRF5.  This CGGGG indel is part of a polymorphic repetitive DNA 
region that contains either 3 or 4 CGGGG units, where the insertion of an additional 
CGGGG unit (the 4 x CGGGG allele) is the risk allele for IBD. A possible function of 
the insertion of CGGGG as a cis-acting regulatory element is suggested by the prediction 
that it creates an additional binding site for the transcription factor SP1. In this 
polymorphic region 3 CGGGG repeats constitute 2 SP1 binding sites, and 4 CGGGG 
constitute 3 SP1 binding sites. Our data from EMSA performed on nuclear extract from 
blood cells in the present study support this prediction. We speculate that the creation of 
an additional binding site for the transcription factor SP1, could increase transcription of 
the IRF5 gene. However further functional studies are necessary to clarify if there is an 
increased expression of IRF5 as a consequence of a specific enhanced binding of SP1 to 
the 4 x CGGGG allele of IRF5 in tissues that are relevant for IBD. Indirect support for 
this suggestion comes from previously shown, constitutive binding of SP1 at two adjacent 
sites in IRF4, which has been observed in HTLV-I-infected cells (43). Constitutive 
binding of SP1 to IRF1 has also been observed, and is required for G1 activation of the 
  10
transcription in the prolactin signalling (44). A similar sequence (GGCGGGG) is present 
in the promoter of three IRF genes (IRF1, IRF4 and IRF5). The specific binding of SP1 
to these sequences shown by supershift assays on IRF1 and IRF4 support the predicted 
binding of SP1 to the IRF5 gene (43, 44). Considering the role of IRF5 in the TLR 
pathway, increased expression of IRF5 could lead to an increased production of pro-
inflammatory cytokines and the perpetuation of inflammation, but further studies on the 
role of IRF5 in the pathogenesis of IBD are required. 
 
The association of IRF5 with SLE and RA has been reported (28, 30), but the causal 
variant(s) have not yet been identified in these diseases.  Several pathogenic mechanisms 
have been proposed, such as differential immune response depending on the expressed 
IRF5 isoforms, enhanced cytokine production or alteration of apoptosis (30, 32). The 
polymorphisms in IRF5 are correlated and different polymorphisms or combinations of 
them could also result in different pathologies, demonstrating the complexity of the role 
of IRF5 in immune diseases. Here we show a strong association of IRF5 with two other 
immune diseases, CD and UC. A more complete characterization of the genetic variation 
of IRF5 genetic and functional studies are now necessary to fully understand the 
underlying mechanisms by which IRF5 is involved in IBD. 
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Materials and methods 
Cohorts 
Our cohort contained 1007 IBD patients from Wallonia, Belgium, of which 748 were 
diagnosed with Crohn disease (CD), 254 with ulcerative colitis (UC) and five with 
indeterminate colitis (IC). Healthy individuals (N = 241) attending the University 
Hospital of Liège and blood donors were used as controls. A second cohort of 687 IBD 
patients from Leuven, of which 488 were CD patients, 192 were UC patients and 7 were 
IC was also analyzed.  A set of 311 volunteer blood donors served as unrelated control 
individuals for these patients. All patients and controls included in the study gave their 
informed consent. Ethical approvals for the study were obtained from the ethics 
committees of the University Hospitals of Liège and Leuven. 
 
Genotyping 
Ten SNPs and two insertion-deletion polymorphisms (indels) in the IRF5 gene were 
genotyped. Nine SNPs (rs729302 rs3757385, rs2004640, rs3807306, rs2070197, 
rs10954213, rs11770589, rs2280714, rs12539741) were genotyped by fluorescent 
minisequencing using the multiplex SNPstream system (Beckman Coulter) (45). The 
SNP rs4728142 was genotyped by a homogeneous template directed-dye terminator 
assay with fluorescence polarization detection (FP-TDI [Perkin Elmer]) (46).  The two 
indels, a CGGGG indel in the promoter region of the IRF5 gene and a 30 bp indel in exon 
6 of the IRF5 gene were genotyped after amplification with a fluorescent PCR primer, 
and the amplified fragments were analyzed using an ABI3100 sequencer (Applied 
Biosystems, Foster City, USA). The fragment analysis was performed using the 
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GeneMapper v.3.7. software (Applied Biosystems, Foster City, USA). The sequences of 
the PCR and minisequencing primers are provided in Supplementary Table 1. The 
genotype call rate was 96,7% and the reproducibility was 99,7%, according to replication 
of 15.6% of the genotypes.  
 
Electrophoretic mobility shift assay (EMSA) 
Complementary 5’ biotinylated and unmodified 30-37 bp oligonucleotides were designed 
for both alleles of the CGGGG indel (3 x CGGGG probe: 5’-
AGTGGATTCGCGGGGCGGGGCGGGGCACTGCCCGCGC-3’ and 4 x CGGGG 
5’-AGTGGATTCGCGGGGCGGGGCGGGGCGGGGCACTGCC-3’). The 
oligonucleotides were obtained from Integrated DNA Technologies (IDT Inc, Coralville, 
IA, USA). The complementary oligonucleotides were allowed to anneal in 10 mM Tris–
HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA to generate double stranded probes for the 
EMSA reaction. Twenty fmoles of the labeled double stranded probes were incubated 
with 3 µl of nuclear extract prepared from blood cells, using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents Kit (Pierce Biotechnology, Rockford, IL, USA), in a 
freshly made binding buffer containing 12 mM HEPES pH 7.4, 5 mM MgCl2, 60 mM 
KCl, 1% glycerol, 0.05% NP-40, 50 µg/µl BSA, 1 mM DTT, 0.5 mM EDTA with 50 
ng/µl of poly(dI-dC)⋅poly(dI-dC) (Amersham Biosciences, Piscataway, NJ, USA) and 
Halt™ Protease Inhibitor Cocktail (Pierce Biotechnology, Rockford, IL, USA) in a final 
volume of 20 µl.  The mixtures were incubated at room temperature for 20 minutes, and 
analyzed using electrophoresis on 6% polyacrylamide gels (Bio-Rad Laboratories, 
Hercules, CA, USA). The gels were run for 1.5 h at 100 V, followed by transfer to 
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Hybond-N+ nylon membranes (Buckinghamshire, England) in 0.5 x TBE for 1 h at 550 
mA, using a Criterion Blotter (Bio-Rad Laboratories, Hercules, CA, USA). The 
Chemiluminescent Nucleic Acid Detection Module (Pierce Biotechnology, Rockford, IL, 
USA) was used to visualize the biotinylated oligonucleotide signals on the membranes 
using a ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, CA, USA).  
 
Statistical analysis 
For each tested polymorphisms, the quality of the genotype data was confirmed for both 
cohorts by testing for Hardy-Weinberg equilibrium in the control samples, using the Chi-
square test and Haploview 3.32 (47). Pairwise linkage disequilibrium values D’- and r2- 
were determined using the Haploview v3.32 software. The haplotypes were constructed 
using the FastPhase software (48). Allele and genotypes frequencies were compared 
between patient and healthy controls by a Chi square test. For CD and UC, the allele 
frequencies were compared between the disease subgroups and all controls. Differences 
in haplotype frequencies were determined by Fisher’s exact test.  Odds ratios were 
calculated using the formula [a(r)/b(r)]/ [a(nr)/b(nr)], where a and b stand  for the allele 
counts in patients and controls, respectively, with the risk-allele as (r) and the non-risk 
allele as (nr). The combined analyses were performed by pooling the genotype data from 
the individual cases and controls from both cohorts. 
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Legends to the figures 
 
Figure 1 
Illustration of the IRF5 gene. a. Exons are represented as boxes; coding exons in white. 
The genotyped polymorphisms and their location are represented. b. Sequences of the 
two insertions (underlined). The binding sites for the transcription factor SP1 are 
represented by boxes, the white box corresponding to the third SP1 binding site created 
by the insertion of the 5bp CGGGG. 
 
Figure 2 
Plot of pair-wise linkage disequilibrium values (r2) between IRF5 polymorphisms. The 
LD plot has been generated with the “snp.plotter”-option of the R-software package. 
 
Figure 3  
Electrophoretic mobility shift assay for the CGGGG indel. Samples loaded in lanes 1-3 
contain: 1) labeled probe only; 2) labeled probe and nuclear extract; 3) labeled probe, 
nuclear extract and the unlabeled probe, which is added as a competitor in 100-fold 






Table 1. Potential effects and disease associations for the genotyped polymorphisms   
SNP Potential functional role Association References 
rs729302 Promoter region SLE 
Sigurdsson et al (28), Graham R.R. et al. (29, 
32)  
rs4728142 Promoter region, variation in IRF5 expresion level SLE 
Graham RR et al. (32) (34), Graham D.S.G. et 
al. (49) 
rs3757385 Promoter region RA Sigurdsson et al. (30) 
CGGGG indel Promoter region  
Chromosome position 128365152 (NCBI build 
36.2.) 
rs2004640 
Altered consensus splice donor site / intron, variation in IRF5 
expresion level SLE,RA 
Sigurdsson et al. (28) (30) Graham R.R. et al. 
(29, 32),Graham D.S.G. et al. (49) 
rs3807306 Intron SLE,RA 
Sigurdsson et al .(30), Graham D.S.G. et al. 
(49) 
30bp indel Alteration of PEST domain, variation in IRF5 expresion level  Graham R.R. et al.(32)  
rs2070197 Variation in IRF5 expresion level SLE Graham R.R. et al. (32) 
rs10954213 
Altered length of he IRF5 3' UTR, variation in IRF5 expresion 
level SLE 
Graham R.R. et al. (32), Graham D.S.G. et al. 
(49) 
rs11770589 3’ UTR    
rs2280714 Variation in IRF5 expresion level SLE 
Cheung V et al.(50), Graham R.R. et al. (29, 
32) 










Table 2: Single marker association results. Main cohort. 

















CD    
Patients 








rs729302 A/C A 0.40 0.35 0.37 0.30 0.068 0.25 0.0027 0.80       
(0.64-1.01)
0.87       
(0.69-1.10)
0.64      
(0.48-0.85) 
rs4728142 A/G A 0.36 0.45 0.42 0.51 0.0016 0.029 0.000010 1.46      
(1.15-1.84)
1.32      
(1.03-1.68)
1.90      
(1.43-2.52) 
rs3757385 G/T G 0.42 0.37 0.38 0.35 0.072 0.15 0.028 0.81      
(0.65-1.01)
0.84      
(0.66-1.06)






Ins 0.30 0.43 0.41 0.51 0.000019 0.00068 0.000000053 1.81      
(1.37-2.39)
1.63      
(1.23-2.17)
2.42      
(1.76-3.34) 
rs2004640 T/G T 0.45 0.5 0.48 0.55 0.071 0.27 0.0036 1.23       
(0.99-1.54)
1.15       
(0.91-1.44)
1.51       
(1.15-1.98) 
rs3807306 T/G T 0.40 0.48 0.46 0.53 0.0056 0.046 0.00023 1.37       
(1.10-1.71)
1.27       
(1.01-1.60)
1.69       
(1.28-2.22) 
30bp indel ½ Del 0.46 0.52 0.52 0.46 0.021 0.042 0.022 1.30       
(1.04-1.62)
1.27      
(1.01-1.60)
0.73      
(0.55-0.95) 
rs2070197 C/T C 0.08 0.09 0.08 0.10 1 0.92 0.63 1.03       
(0.69-1.53)
0.98       
(0.65-1.48)
1.16      
(0.71-1.86) 
rs10954213 A/G A 0.46 0.39 0.40 0.37 0.018 0.050 0.011 0.76      
(0.61-0.95)
0.79       
(0.63-0.99)
0.69      
(0.52-0.91) 
rs11770589 A/G A 0.55 0.48 0.52 0.46 0.018 0.036 0.018 0.76       
(0.61-0.95)
1.28      
(1.02-1.6) 
0.72      
(0.55-0.94) 
rs2280714 T/C T 0.39 0.35 0.36 0.34 0.10 0.16 0.072 0.82      
(0.66-1.03)
0.84      
(0.67-1.06)
0.77      
(0.58-1.02) 
rs12539741 T/C T 0.07 0.09 0.08 0.10 0.46 0.58 0.25 1.22       
(0.79-1.90)
1.16      
(0.74-1.83) 






Table 3: Single marker association results. Confirmatory cohort. 



























rs729302 A/C A 0.36 0.36 0.37 0.34 0.91 0.54 0.56 1.01      
(0.82-1.25) 
1.07      
(0.86-1.34)
0.91      
(0.69-1.21)
rs4728142 A/G A 0.39 0.43 0.42 0.43 0.17 0.29 0.26 1.15      
(0.94-1.42) 
1.13      
(0.91-1.40)
1.17      
(0.89-1.55)
rs3757385 G/T G 0.38 0.37 0.37 0.40 0.79 0.74 0.57 0.97      
(0.79-1.19) 
0.96      
(0.77-1.20)






Ins 0.35 0.46 0.46 0.46 0.000032 0.00014 0.0023 1.59      
(1.28-1.98) 
1.57      
(1.24-1.98)
1.59      
(1.18-2.14)
rs2004640 T/G T 0.49 0.50 0.50 0.50 0.72 0.83 0.89 1.04       
(0.85-1.27) 
1.03      
(0.83-1.27)
1.02       
(0.78-1.34)
rs3807306 T/G T 0.47 0.49 0.48 0.5 0.51 0.71 0.41 1.07       
(0.88-1.31) 
1.04       
(0.84-1.29)
1.13       
(0.86-1.48)
30bp indel ½ Del 0.47 0.49 0.49 0.49 0.58 0.42 0.68 1.06       
(0.87-1.29) 
1.09       
(0.88-1.3) 
1.06       
(0.82-1.39)
rs2070197 C/T C 0.08 0.10 0.11 0.092 0.12 0.057 0.54 1.34      
(0.94-1.91) 
1.43      
(0.99-2.09)
1.17      
(0.73-1.89)
rs10954213 A/G A 0.39 0.39 0.39 0.40 0.87 0.87 0.72 0.98      
(0.79-1.20) 
0.98      
(0.79-1.20)
1.05      
(0.80-1.39)
rs11770589 A/G A 0.47 0.49 0.50 0.49 0.54 0.39 0.58 1.07      
(0.87-1.3) 
1.10       
(0.89-1.36)
1.09      
(0.83-1.42)
rs2280714 T/C T 0.34 0.34 0.34 0.36 0.91 0.86 0.52 0.98      
(0.79-1.21) 
0.97      
(0.78-1.22)
1.1        
(0.83-1.45)
rs12539741 T/C T 0.080 0.10 0.11 0.092 0.10 0.057 0.54 1.35      
(0.94-1.92) 
1.45        
(1-2.10) 








Table 4: Single marker association results case/controls from combined cohorts 





















rs729302 A/C A 0.38 0.36 0.37 0.32 0.26 0.81 0.011 0.91      
(0.79-1.07) 
0.98      
(0.83-1.15)
0.77       
(0.63-0.94) 
rs4728142 A/G A 0.38 0.42 0.42 0.48 0.0014 0.029 0.000042 1.28        
(1.1-1.49) 
1.20       
(1.02-1.40)
1.50      
(1.24-1.83) 
rs3757385 G/T G 0.40 0.37 0.37 0.37 0.19 0.30 0.28 0.90      
(0.78-1.05) 
0.92      
(0.78-1.07)






Ins 0.33 0.44 0.43 0.49 0.000000014 0.0000033 0.00000000079 1.62      
(1.37-1.91) 
1.51      
(1.27-1.80)
1.93      
(1.56-2.38) 
rs2004640 T/G T 0.47 0.50 0.49 0.53 0.16 0.46 0.027 1.11       
(0.96-1.29) 
1.06      
(0.91-1.24)
1.24      
(1.03-1.50) 
rs3807306 T/G T 0.44 0.48 0.47 0.52 0.027 0.17 0.0018 1.18      
(1.02-1.37) 
1.11      
(0.95-1.30)
1.36      
(1.12-1.64) 
30bp indel ½ Del 0.50 0.48 0.49 0.47 0.30 0.51 0.27 0.92      
(0.80-1.07) 
0.95      
(0.81-1.10)
0.90      
(0.74-1.08) 
rs2070197 C/T C 0.081 0.094 0.094 0.094 0.27 0.27 0.39 1.17      
(0.89-1.52) 
1.17      
(0.89-1.54)
1.17      
(0.84-1.67) 
rs10954213 A/G A 0.42 0.39 0.39 0.38 0.11 0.21 0.15 0.88      
(0.76-1.03) 
0.90      
(0.77-1.06)
0.87      
(0.71-1.05) 
rs11770589 A/G A 0.50 0.49 0.49 0.48 0.30 0.48 0.29 0.92      
(0.80-1.07) 
0.95      
(0.81-1.10)
0.90      
(0.75-1.09) 
rs2280714 T/C T 0.36 0.35 0.35 0.35 0.31 0.41 0.48 0.92      
(0.79-1.08) 
0.93       
(0.80-1.10)
0.93      
(0.77-1.13) 
rs12539741 T/C T 0.077 0.095 0.096 0.095 0.11 0.11 0.19 1.25      
(0.95-1.65) 
1.26       
(0.95-1.68)















CD: Crohn disease 
CTLA-4: Cytotoxic T-lymphocyte antigen-4 
GD: Graves' disease 
GWA: Genome wide association 
IBD: Inflammatory bowel diseases 
IC: Indeterminate colitis 
IFN: Interferon 
IL: Interleukin 
Indel: Insertion / deletion 
IRF5: Interferon regulatory factor 5 
RA: Rheumatoid arthritis 
SLE: Systemic lupus erythematosus 
SNP: Single nucleotide polymorphism  
SP1: Specificity protein 1 
T1D: Type 1 diabetes 
TLR: Toll-like receptor 
UC: ulcerative colitis 
WTCCC: Welcome Trust Case Control Consortium 
 
  31
